Table 2.
Age distribution of included patients of which test results of all 3 assays are available (n = 11,333).
| Age (years) | Included samples (N) | Age distribution of tested cohort (DuSC) | Age distribution of Dutch screening population | HC2 hrHPV prevalence %(N) |
cobas hrHPV prevalence %(N) |
Aptima hrHPV prevalence %(N) |
Overall hrHPV prevalence |
|---|---|---|---|---|---|---|---|
| 29–33 | 1,191 | 10.5% | 10.5% | 19.1% (228) | 19.7% (235) | 17.3% (206) | 18.7 ± 1.2% |
| 34–38 | 1,317 | 11.6% | 11.7% | 11.7% (154) | 11.5% (152) | 10.6% (140) | 11.3 ± 0.6% |
| 39–43 | 1,775 | 15.7% | 16.3% | 9.0% (159) | 8.0% (142) | 7.3% (130) | 8.1 ± 0.9% |
| 44–48 | 1,928 | 17.0% | 16.9% | 7.7% (148) | 7.1% (137) | 6.3% (122) | 7.0 ± 0.7% |
| 49–53 | 1,870 | 16.5% | 16.4% | 6.3% (117) | 5.4% (101) | 5.4% (101) | 5.7 ± 0.5% |
| 54–58 | 1,703 | 15.0% | 14.7% | 5.4% (92) | 5.0% (86) | 4.9% (84) | 5.1 ± 0.3% |
| 59–63 | 1,549 | 13.7% | 13.6% | 3.9% (61) | 4.3% (66) | 4.3% (66) | 4.2 ± 0.2% |
| Total (N) | 11,333 | 959 | 919 | 849 |
Number of included samples per age group and age distribution of study cohort vs age distribution of the Dutch screening program; and hrHPV prevalences per assay and overall mean